Recent News
SEP 21, 2023
SEP 21, 2022
DEC 9, 2021
MAY 4, 2021
FEB 2, 2021
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
Careers
Abpro offers competitive salaries and generous benefits with the opportunity to learn and grow in an employee-driven culture. We are seeking individuals with infectious enthusiasm, passion, and conviction who will be committed to our core values and mission. If you thrive in an upbeat, energetic, collaborative environment where every individual counts, we are looking for you!